Cargando…
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of su...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449272/ https://www.ncbi.nlm.nih.gov/pubmed/36068599 http://dx.doi.org/10.1186/s13063-022-06680-4 |
_version_ | 1784784258353594368 |
---|---|
author | Love, Sharon B. Cafferty, Fay Snowdon, Claire Carty, Karen Savage, Joshua Pallmann, Philip McParland, Lucy Brown, Louise Masters, Lindsey Schiavone, Francesca Hague, Dominic Townsend, Stephen Amos, Claire South, Annabelle Sturgeon, Kate Langley, Ruth Maughan, Timothy James, Nicholas Hall, Emma Kernaghan, Sarah Bliss, Judith Turner, Nick Tutt, Andrew Yap, Christina Firth, Charlotte Kong, Anthony Mehanna, Hisham Watts, Colin Hills, Robert Thomas, Ian Copland, Mhairi Bell, Sue Sebag-Montefiore, David Jones, Robert Parmar, Mahesh K. B. Sydes, Matthew R. |
author_facet | Love, Sharon B. Cafferty, Fay Snowdon, Claire Carty, Karen Savage, Joshua Pallmann, Philip McParland, Lucy Brown, Louise Masters, Lindsey Schiavone, Francesca Hague, Dominic Townsend, Stephen Amos, Claire South, Annabelle Sturgeon, Kate Langley, Ruth Maughan, Timothy James, Nicholas Hall, Emma Kernaghan, Sarah Bliss, Judith Turner, Nick Tutt, Andrew Yap, Christina Firth, Charlotte Kong, Anthony Mehanna, Hisham Watts, Colin Hills, Robert Thomas, Ian Copland, Mhairi Bell, Sue Sebag-Montefiore, David Jones, Robert Parmar, Mahesh K. B. Sydes, Matthew R. |
author_sort | Love, Sharon B. |
collection | PubMed |
description | BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of successful platform protocols together to present some operational recommendations. METHODS: Representatives of six UK clinical trials units with experience in running late-phase platform protocols attended a 1-day meeting structured to discuss various practical aspects of running these trials. We report and give guidance on operational aspects which are either harder to implement compared to a traditional late-phase trial or are specific to platform protocols. RESULTS: We present a list of practical recommendations for trialists intending to design and conduct late-phase platform protocols. Our recommendations cover the entire life cycle of a platform trial: from protocol development, obtaining funding, and trial set-up, to a wide range of operational and regulatory aspects such as staffing, oversight, data handling, and data management, to the reporting of results, with a particular focus on communication with trial participants and stakeholders as well as public and patient involvement. DISCUSSION: Platform protocols enable many questions to be answered efficiently to the benefit of patients. Our practical lessons from running platform trials will support trial teams in learning how to run these trials more effectively and efficiently. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06680-4. |
format | Online Article Text |
id | pubmed-9449272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94492722022-09-07 Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units Love, Sharon B. Cafferty, Fay Snowdon, Claire Carty, Karen Savage, Joshua Pallmann, Philip McParland, Lucy Brown, Louise Masters, Lindsey Schiavone, Francesca Hague, Dominic Townsend, Stephen Amos, Claire South, Annabelle Sturgeon, Kate Langley, Ruth Maughan, Timothy James, Nicholas Hall, Emma Kernaghan, Sarah Bliss, Judith Turner, Nick Tutt, Andrew Yap, Christina Firth, Charlotte Kong, Anthony Mehanna, Hisham Watts, Colin Hills, Robert Thomas, Ian Copland, Mhairi Bell, Sue Sebag-Montefiore, David Jones, Robert Parmar, Mahesh K. B. Sydes, Matthew R. Trials Methodology BACKGROUND: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of successful platform protocols together to present some operational recommendations. METHODS: Representatives of six UK clinical trials units with experience in running late-phase platform protocols attended a 1-day meeting structured to discuss various practical aspects of running these trials. We report and give guidance on operational aspects which are either harder to implement compared to a traditional late-phase trial or are specific to platform protocols. RESULTS: We present a list of practical recommendations for trialists intending to design and conduct late-phase platform protocols. Our recommendations cover the entire life cycle of a platform trial: from protocol development, obtaining funding, and trial set-up, to a wide range of operational and regulatory aspects such as staffing, oversight, data handling, and data management, to the reporting of results, with a particular focus on communication with trial participants and stakeholders as well as public and patient involvement. DISCUSSION: Platform protocols enable many questions to be answered efficiently to the benefit of patients. Our practical lessons from running platform trials will support trial teams in learning how to run these trials more effectively and efficiently. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06680-4. BioMed Central 2022-09-06 /pmc/articles/PMC9449272/ /pubmed/36068599 http://dx.doi.org/10.1186/s13063-022-06680-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Methodology Love, Sharon B. Cafferty, Fay Snowdon, Claire Carty, Karen Savage, Joshua Pallmann, Philip McParland, Lucy Brown, Louise Masters, Lindsey Schiavone, Francesca Hague, Dominic Townsend, Stephen Amos, Claire South, Annabelle Sturgeon, Kate Langley, Ruth Maughan, Timothy James, Nicholas Hall, Emma Kernaghan, Sarah Bliss, Judith Turner, Nick Tutt, Andrew Yap, Christina Firth, Charlotte Kong, Anthony Mehanna, Hisham Watts, Colin Hills, Robert Thomas, Ian Copland, Mhairi Bell, Sue Sebag-Montefiore, David Jones, Robert Parmar, Mahesh K. B. Sydes, Matthew R. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units |
title | Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units |
title_full | Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units |
title_fullStr | Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units |
title_full_unstemmed | Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units |
title_short | Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units |
title_sort | practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced uk clinical trials units |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449272/ https://www.ncbi.nlm.nih.gov/pubmed/36068599 http://dx.doi.org/10.1186/s13063-022-06680-4 |
work_keys_str_mv | AT lovesharonb practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT caffertyfay practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT snowdonclaire practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT cartykaren practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT savagejoshua practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT pallmannphilip practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT mcparlandlucy practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT brownlouise practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT masterslindsey practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT schiavonefrancesca practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT haguedominic practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT townsendstephen practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT amosclaire practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT southannabelle practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT sturgeonkate practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT langleyruth practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT maughantimothy practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT jamesnicholas practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT hallemma practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT kernaghansarah practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT blissjudith practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT turnernick practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT tuttandrew practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT yapchristina practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT firthcharlotte practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT konganthony practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT mehannahisham practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT wattscolin practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT hillsrobert practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT thomasian practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT coplandmhairi practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT bellsue practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT sebagmontefioredavid practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT jonesrobert practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT parmarmaheshkb practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits AT sydesmatthewr practicalguidanceforrunninglatephaseplatformprotocolsforclinicaltrialslessonsfromexperiencedukclinicaltrialsunits |